The outcomes of patients with septic shock treated with propafenone compared to amiodarone for supraventricular arrhythmias are related to end-systolic left atrial volume.
Eur Heart J Acute Cardiovasc Care
; 13(5): 414-422, 2024 May 28.
Article
en En
| MEDLINE
| ID: mdl-38372622
ABSTRACT
AIMS:
A recently published trial has shown no differences in outcomes between patients with new-onset supraventricular arrhythmia (SVA) in septic shock treated with either propafenone or amiodarone. However, these outcome data have not been evaluated in relation to the presence or absence of a dilated left atrium (LA). METHODS ANDRESULTS:
Patients with SVA and a left ventricular ejection fraction ≥ 35% were randomized to receive intravenous propafenone (70â mg bolus followed by 400-840â mg/24â h) or amiodarone (300â mg bolus followed by 600-1800â mg/24â h). They were divided into groups based on whether their end-systolic left atrial volume (LAVI) was ≥40â mL/m². The subgroup outcomes assessed were survival at ICU discharge, 1 month, 3 months, 6 months, and 12 months. Propafenone cardioverted earlier (P = 0.009) and with fewer recurrences (P = 0.001) in the patients without LA enlargement (n = 133). Patients with LAVI < 40â mL/m2 demonstrated a mortality benefit of propafenone over the follow-up of 1 year [Cox regression, hazard ratio (HR) 0.6 (95% CI 0.4; 0.9), P = 0.014]. Patients with dilated LA (n = 37) achieved rhythm control earlier in amiodarone (P = 0.05) with similar rates of recurrences (P = 0.5) compared to propafenone. The outcomes for patients with LAVI ≥ 40â mL/m2 were less favourable with propafenone compared to amiodarone at 1 month [HR 3.6 (95% CI 1.03; 12.5), P = 0.045]; however, it did not reach statistical significance at 1 year [HR 1.9 (95% CI 0.8; 4.4), P = 0.138].CONCLUSION:
Patients with non-dilated LA who achieved rhythm control with propafenone in the setting of septic shock had better short-term and long-term outcomes than those treated with amiodarone, which seemed to be more effective in patients with LAVI ≥ 40â mL/m². TRIAL REGISTRATION ClinicalTrials.gov identifier NCT03029169, registered on 24 January 2017.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Choque Séptico
/
Propafenona
/
Taquicardia Supraventricular
/
Atrios Cardíacos
/
Amiodarona
/
Antiarrítmicos
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Eur Heart J Acute Cardiovasc Care
Año:
2024
Tipo del documento:
Article